"As an advocate, observer, and proponent of behavioral finance theory, few stocks in recent history have provided me with as fertile a platform for observation and analysis as the Valencia, California-based biotechnology company, MannKind (NASDAQ:
MNKD). Like most developmental stage biotechnology entities, MannKind has traveled a road riddled with obstacles, setbacks, capital raises and criticisms for the better part of a decade. Moreover, and more specific to the company's recently approved diabetes drug Afrezza, the company has navigated the tumultuous waters of FDA scrutiny, the creative strategies of
accomplished hedge fund managers and their own interests, and the unrelenting pressure of remorseless short sellers who never run out of subjective points of citation capable of creating a thinly veiled illusion of validity. It is the elaborate combination of all of these factors which have provided a foundation for MannKind to evolve into what is, arguably, the ultimate
"battleground stock."
Great post.